ASBP

Aspire BioPharma, Inc.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$7.27M
P/E Ratio
EPS
$-7.09
Beta
0.15
52W High
$1050.36
52W Low
$3.31
50-Day MA
$4.59
200-Day MA
$5.09
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Aspire BioPharma, Inc.

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)34,560
Gross Profit (TTM)5,630
EBITDA
Operating Margin-5759.00%
Return on Equity0.00%
Return on Assets-74.70%
Revenue/Share (TTM)$0.43
Book Value$23.10
Price-to-Book2.08
Price-to-Sales (TTM)210.28
EV/Revenue106.66
EV/EBITDA
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$1.30M
Float$1.22M
% Insiders5.91%
% Institutions0.99%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Latest News

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

The brand expands nationwide distribution on Amazon, delivering a waterless, rapid-dissolve 50 mg caffeine powder built for active, on-the-go lifestyles. ESTERO, FL / ACCESS Newswire / June 24, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary Buzz Bomb Caffeine Company LC today announced the nationwide Amazon launch of its innovative BUZZ BOMB™ 50mg caffeine stick packs.

Accesswire6/24/2026Neutral
Aspire Biopharma Issues Shareholder Letter

ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today issued the following letter to shareholders from Chief Executive Officer Kraig Higginson. Dear Fellow Shareholders, 2026 is shaping up to be a defining year for Aspire Biopharma Holdings.

Accesswire5/28/2026Neutral
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

ESTERO, FL / ACCESS Newswire / May 7, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it will effect a one-for-thirty (1:30) reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on May 11, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Aspire has requested that its Common Stock begin trading on May 11, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol "ASBP".

Accesswire5/7/2026Neutral
Aspire Biopharma Announces $5.0 Million Share Repurchase Program

ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that its Board of Directors (the "Board") has authorized the repurchase of up to $5.0 million of the Company's common stock. The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced Binding Letter of Intent (LOI) to acquire Dura Driver Control Systems (DCS).

Accesswire4/27/2026Neutral
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Company secures Commitment Letter from a leading financial institution of up to $22.5M to finance proposed acquisition of Dura Control Systems (DCS) LOI to acquire DCS, a leading global automotive supplier with $200M+ in 2025 revenue, is not expected to require new equity raise to consummate the purchase ESTERO, FL / ACCESS Newswire / April 20, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company") today announced that it has closed the second and final tranche of the private placement announced on February 11, 2026 (the "Offering") for the purchase and sale of 26,250 shares of Series A Convertible Preferred Stock. Pursuant to the closing of the second and final tranche of the Offering, the Company issued an aggregate of 12,500 Preferred Shares for gross proceeds of $10.0 million.

Accesswire4/20/2026Neutral
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

ESTERO, FL / ACCESS Newswire / April 16, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced it has entered into a Letter of Intent (LOI) to acquire Dura Driver Control Systems ("DCS"), a premier designer and manufacturer of automotive driver control systems that also apply to other industrial applications. Management of DCS will be bolstered by the addition of a team from Lakewood & Company with more than 100 years' collective experience within the automotive industry.

Accesswire4/16/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026